Ectopic pregnancy (EP) is the most important cause of maternal death in the first trimester accounting for 9 -13% of all pregnancy-related deaths (1). Despite the use of transvaginal sonography and high sensitive quantitative beta-hCG assays for diagnosis, nearly 40-50% of all EPs may be initially misdiagnosed (2). Therefore, several biomarkers have been investigated for early diagnosis of EP. Activin A, a dimeric glycoprotein belonging to the TGF- superfamily, has been highlighted among these "new biomarkers" (3). Florio et al reported that serum activin A levels can be markedly lower in women with tubal EP than those levels found either during normal intrauterine pregnancy or spontaneous miscarriage (4). The authors showed that a cut-off value of 0.37 ng/mL have 100% and 99.6% of sensitivity and specificity, respectively for predicting EP. Conversely, Kirk et al demonstrated in another elegant study that activin A has much lower sensitivity and specificity when used as a single biomarker for the diagnosis of EP (5). Bearing on these considerations, it is clear that this subject still needs to be carefully evaluated and it prompted us to develop this project where we compared serum activin A levels in women at first trimester of normal pregnancy to women with tubal EP.
. Serum levels of activin A in women with ectopic pregnancy and normal pregnancy at 5-6 weeks gestational age (pg/mL).
Activin A has been reported to play an important role in the implantation process and inadequate levels of this molecule may be related to either an inappropriate implantation site or trophoblastic alterations (6) . Therefore, some authors have investigated activin A as a biomarker for early diagnosis of EP. In this work we demonstrated that serum activin A levels could not discriminate between an EP from a normal intrauterine pregnancy (p=0.206) when an adnexial mass was found by transvaginal scan. These results are in agreement with those reported by Kirk et al regarding pregnancy of unknown location, although we had a different methodology (5) .
Florio et al demonstrated that an activin A cut-off value of 0.37 ng/mL has 100% and 99.6% of sensitivity and specificity for diagnosis of EP (4). Despite we had a small number of cases it is possible to suggest that serum activin A may have a peculiar curve in EP as none of our results were higher than the cut-off value established by Florio et al even with identifiable adnexial mass (4) . Therefore, we suggest that a multicentre study should be developed to
